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Malignant pleural mesothelioma (MPM) is associated with asbestos exposure. Asbestos can induce chronic inflammation which in
turn can lead to silencing of tumour suppressor genes. Wnt signaling pathway can be affected by chronic inflammation and is
aberrantly activated in many cancers including colon and MPM. SFRP genes are antagonists of Wnt pathway, and SFRPs are
potential tumour suppressors in colon, gastric, breast, ovarian, and lung cancers and mesothelioma. This study investigated the
expression and DNA methylation of SFRP genes in MPM cells lines with and without demethylation treatment. Sixty-six patient
FFPE samples were analysed and have showed methylation of SFRP2 (56%) and SFRP5 (70%) in MPM. SFRP2 and SFRP5
tumour-suppressive activity in eleven MPM lines was confirmed, and long-term asbestos exposure led to reduced expression of
the SFRP1 and SFRP2 genes in the mesothelium (MeT-5A) via epigenetic alterations. Finally, DNA methylation of SFRPs is
detectable in MPM patient plasma samples, with methylated SFRP2 and SFRP5 showing a tendency towards greater abundance
in patients. These data suggested that SFRP genes have tumour-suppresive activity in MPM and that methylated DNA from
SFRP gene promoters has the potential to serve as a biomarker for MPM patient plasma.
1. Introduction
Malignant pleural mesothelioma (MPM) is an aggressive and
invariably fatal malignancy associated with asbestos expo-
sure. The exact mechanism by which asbestos exposure leads
to MPM carcinogenesis is not yet understood. It is known
that asbestos is capable of inducing chronic inflammation
and that chronic inflammation is capable of inducing tumour
suppressor gene (TSG) silencing which is a driver of cancer.
However, a much better understanding of the mechanism
by which asbestos exposure leads to MPM is needed, so that
the molecular players in the mechanism can be used as new
molecular targets for diagnosis and treatment of MPM [1, 2].
It has been proposed that asbestos silicates attract and
bind cations and that asbestos needles in the lungs will both
retain the ions on the asbestos fibre surface and leach them
into the cellular milieu [3], generating reactive oxygen species
(ROS) and free radicals that begin the processes of cellular
and DNA damage and genotoxicity, driving carcinogenesis
[4, 5]. The high iron content of some asbestos fibres, as well
as the propensity for asbestos to adsorb iron in vivo, has led
some authors to suggest that iron-induced Fenton reactions
contribute to increased ROS generation, inflammation, and
carcinogenesis. It has been shown that asbestos exposure
does not directly transform primary human mesothelial cells
in tissue culture and instead induces inflammation [6–9].
Chronic inflammation caused by exposure of serosal surfaces
to asbestos fibres is likely to represent a central factor in the
carcinogenesis of MPM [10, 11].
The mechanism by which asbestos-induced chronic
inflammation progresses to MPM carcinogenesis may be
through epigenetic changes [10, 11]. A relationship between
inflammation and promoter DNA hypermethylation has
been documented in many forms of cancer, including
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MPM [11]. Dysregulation of epigenetic transcriptional con-
trol, as well as aberrant promoter DNA methylation and
histone modifications in particular, is a fundamental feature
of human malignancies [12]. Asbestos exposure may trigger
MPM formation via this epigenetic DNA methylation route
[10, 13–15], and thus, DNA methylation in MPM is an area
of interest for investigation.
Global DNA methylation has been investigated in MPM,
and a number of genes were found to be methylated at vary-
ing frequencies [10, 16, 17], with the extent of methylation
correlating with self-reported asbestos exposure [16] and
burden of asbestos fibres in the lung [10]. The level of
promoter methylation in MPM cell lines was found to be
higher than that found in normal mesothelial cell cultures,
and higher methylation status was found in tumours com-
pared with normal mesothelium [10, 16]. The extent of
methylation in sarcomatoid MPM was greater for the less
differentiated tumours for which prognosis is poorer than
that seen in epithelioid MPM tumours, suggesting a link
between DNA methylation increase and severity of MPM
disease [17]. Methylation-induced silencing of tumour
suppressor-like miRs has been observed in MPM, suggesting
that aberrant DNAmethylation is involved in MPM carcino-
genesis [18]. Cell-free methylated promoter DNA from pleu-
ral effusion fluid has been used in the diagnosis of malignant
pleural effusion for lung cancer [19], and methylated DNA in
serum was shown to have prognostic significance in MPM
[20]. Therefore, TSG promoter methylation may represent
a potential diagnostic and prognostic biomarker for MPM
and also a potential therapeutic target. Thus, this study inves-
tigated the expression and epigenetic changes to the SFRP
family of TSGs.
SFRPs belong to the family of Wnt pathway antagonists,
and the SFRPs were found to be silenced in colon, gastric,
breast, and lung cancers, with some members silenced in
MPM [21–25]. The Wnt signaling pathway is of particular
interest because comprehensive studies have shown that this
pathway is involved in many cancers. The Wnt pathway is
activated in MPM [26], and inhibition leads to apoptosis in
gastric cancer cells [21]. Silencing of SFRP4 and SRFP5 has
been linked to pemetrexed [26] and cisplatin [22] resistance,
two drugs used in standard MPM treatment. Epigenetic
silencing of the Wnt pathway is well characterized in colon
cancer, a cancer known to be related to chronic inflamma-
tion. Recently, it was shown that the downregulation of SFRP
gene family members in gastric and colorectal cancer is
mediated by methylation silencing [21, 27]. Thus, downregu-
lation of SFRP genes may represent a mechanism of aberrant
Wnt signaling activation [21, 27].
In this study, we studied the mRNA expression and
methylation of SFRPs in a panel of MPM cell lines. We also
adopted an in vitro asbestos exposure model using the
immortalised mesothelial cell line Met-5A and studied the
methylation status and mRNA expression of members of
the known tumour suppressor SFRP gene family. The SFRP
methylation status in a cohort of 66 MPM patient DNA from
FFPE samples was analysed using methylation-specific
primers (MSP). Functional significance of SFRP2 and SFRP5
was studied in 11 MPM cell lines by cloning SFRP2 and
SFRP5 into the cells to increase the expression of these genes
and measure subsequent retardation in growth and colony
formation of MPM cells. Finally, we established a detection
method to study DNA methylation of SFRP genes in MPM
and normal plasma samples with droplet digital PCR
(ddPCR).
2. Materials and Methods
2.1. Cell Lines, Cell Culture, and Treatment. Five MPM cell
lines (H2052, H2452, H28, H226, and MSTO) and the
immortalised mesothelial cell line MeT-5A were obtained
from the American Type Culture Collection (ATCC,
Manassas, VA, USA). The primary mesothelioma cell line
MM05 [28] was generated at the University of Queensland
Thoracic Research Centre (The Prince Charles Hospital,
Brisbane). Ren cells [29] were provided by the Laura Moro
of the University of Piemonte Orientale A. Avogadro,
Novara, Italy. VMC20, VMC23, and VMC40 were generated
by The Medical University of Vienna. The primary MPM
cell line 1137 was established at ADRI from an MPM
patient biopsy. Cells were cultured at 5% CO2, 37
°C, and
95% humidity in RPMI 1640 (MPM cells) or DMEM
(MeT-5A). All media and FBS were from Life Technologies
(Carlsbad, CA, USA).
MeT-5A cells were cultured for 3 months in the presence
or absence of chrysotile (1 μg/cm3). SFRP1 and SFRP2
mRNA expression and promoter DNA methylation were
analysed by quantitative reverse transcription PCR (RT-
qPCR) and quantitative methylation-specific PCR (qMSP)
as detailed below. MPM cells were seeded at 5× 105 cells in a
10 cm2 dish and treated 24h later with 2 μM demethylating
agent 5-aza-2′deoxycytidine (decitabine) every 24 h for 5days.
Cells were then harvested forDNAandRNA (detailed below).
2.2. Tumour Samples. The tumour samples used in this study
are part of a previously reported MPM series to identify
biomarkers [30]. All specimens were laser capture microdis-
sected, guided by pathology marked tumour area. Ethics were
obtained for this study through the Human Research
Ethics Committee at Concord Repatriation General Hospi-
tal, Sydney. Written informed consent from all partici-
pants was obtained.
2.3. Analysis of DNA Methylation. Genomic DNA was
extracted fromMPM cell lines using the DNAMini Kit (Qia-
gen, Valencia, CA, USA) and from MPM FFPE samples
using the FFPE DNA Mini Kit (Qiagen) according to the
manufacturer’s instructions. The methylation status of the
SFRP2 and SFRP5 promoters in MPM cell lines was deter-
mined by MSP or qMSP as described previously [31].
Primers specific for methylated and unmethylated alleles in
MSP were as specified previously [21]. CpGenome universal
methylated DNA (Millipore, Billerica, MA, USA) was used as
a positive control for methylation, and normal buffy coat
(BC) from a healthy donor was used as a control for the
unmethylated locus in each amplification.
2.4. Reverse Transcription and Quantitative Real-Time PCR
(RT-qPCR). Total RNA was extracted from cell lines using
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Trizol reagent (Life Technologies). Reverse transcription
(RT) reactions were performed using 200ng of total RNA
with MMLV first strand cDNA kit (Promega, Madison, WI,
USA) following the manufacturer’s protocol. The expression
of SFRPsmRNA was determined by RT-PCR or quantitative
real-time PCR using the KAPA SYBR Fast qPCR Master Mix
(Sigma) and VII7 QPCR System (Life Technologies). 18S was
used as the reference gene. mRNA expression levels of SFRP
genes were determined using the 2−ΔΔCq method [32] with
normalisation to the 18S gene.
2.5. Expression Plasmids and Transfection. The
pcDNA3.1(+)SFRP2 or pcDNA3.1(+)SFRP5 expression con-
struct was generated by PCR cloning, and the sequence was
verified and subcloned into pcDNA3.1-TOPO expression
vector (Life Technologies) as previously described [20].
Plasmids were introduced into cells by transfection with
X-tremeGENE 9 DNA transfection reagent (Sigma) as per
the manufacturer’s instructions.
2.6. Immunofluorescence of SFRP2 and SFRP5 Expression.
Cells transfected with an SFRP2 or SFRP5 expression con-
struct or empty vector-transfected cells were fixed with 4%
paraformaldehyde (Sigma, St. Louis, MO, USA) in PBS for
15min, washed three times with PBS, and permeabilized with
0.2% Triton X-100 in PBS for 5min. Fixed cells were blocked
with PBS containing 0.1% Triton and 10% fetal bovine serum
for 1 h at room temperature. For immunostaining, cells were
incubated for 2 h at room temperature with rabbit anti-
SFRP2 or anti-SFRP5 and mouse anti-β-actin antibody at
2.5 μg/mL (Abcam) in blocking solution. After three washes
with PBS, cells were incubated for 1 h at room temperature
with Alexa Fluor 596-labeled goat anti-rabbit antibody (Life
Technologies) and Alexa Fluor 488-labeled goat anti-mouse
antibody (Life Technologies). Nuclear counterstaining was
performed with 0.5 μg/mL DAPI. Immunostained cells were
observed under a fluorescence microscope.
2.7. Proliferation Assay. The rate of in vitro cell proliferation
was assessed by quantifying increases in DNA measured by
the SYBR green-based assay. MPM cells were transfected
with an SFRP2 or SFRP5 expression construct or vector con-
trol in 96-well plates, every 24hrs. One set of plates with
medium was removed and the plates were frozen. Relative
cell numbers were determined by staining with 200 μL/well
of SYBR green I (Life Technologies) as described previously
[31]. Proliferation was calculated and presented as a percent-
age of the intensity of control cells at 120 hrs. Each experi-
ment was performed in triplicate.
2.8. Droplet Digital PCR. Primers for the amplification of
methylated SFRP DNA via MSP were optimized using
ddPCR EvaGreen (Bio-Rad) according to the manufacturer’s
recommendations. DNA isolated from 200 μL plasma sam-
ples was bisulfite converted as previously described [21],
and 4 μL from a total of 50 μL converted DNA was used as
a template for ddPCR. For a 20 μL ddPCR reaction, 2× Eva-
Green ddPCR Supermix (Bio-Rad) and primers at a final
concentration of 0.2 μMwere used. Reactions were dispensed
into each well of the droplet generator DG8 cartridge (Bio-
Rad). Each oil compartment of the cartridge was filled with
70 μL of droplet generation oil for EvaGreen (Bio-Rad),
and approximately 15000 to 20000 droplets were generated
in each well with the use of the droplet generator (Bio-Rad
QX200). The entire droplet emulsion volume (40 μL) was
transferred onto a 96-well PCR plate (Eppendorf). The plate
was then heat sealed with a pierceable foil in the PX1 PCR
Plate Sealer (Bio-Rad) and placed in the thermocycler (Bio-
Rad T1000). The thermal cycling conditions used were
95°C for 5min; 40 cycles of 95°C for 30 s, 60°C for 30 s,
72°C for 1min, and a final step at 72°C for 1min. The reac-
tion mixtures were then held at 4°C until needed. The cycled
droplets were read individually with the QX200 droplet-
reader (Bio-Rad) and analysed with QuantaSoft droplet
reader software, version 1.7 (Bio-Rad). The error reported
for a single well was the Poisson 95% confidence interval.
The method of no template controls (NTC) was used to
monitor contaminations and primer-dimer formation and
to determine the cut-off threshold. Normal and plasma
sample-positive populations were then used to calculate the
positive number detected in the sample, and results were
plotted as total copy number detected per sample.
2.9. Statistical Analysis. Student’s t-test was used to compare
the difference in proliferation of SFRP2 or SFRP5 and
control-transfected cells, and p < 0 05 was taken as statisti-
cally significant for differences between the two groups.
Overall survival (OS) was calculated from the time of surgery
to the time of death or last follow-up. Methylation status of
SFRP2 and SFRP5 was used to assess the association of
DNA methylation with OS using the Kaplan-Meier method
and Cox regression. Statistical calculations were carried out
using SPSS version 18.0 for Windows (SPSS Inc., Chicago,
IL, USA). A value of p < 0 05 was considered statistically
significant.
3. Results and Discussion
3.1. SFRP Genes Are Silenced by DNA Hypermethylation in
MPMCell Lines andTumour Samples. SFRP genes are antago-
nists of theWnt-signaling pathway and have been reported to
be aberrantly activated inMPM[25, 26, 33]. Somemembers of
the SFRP gene family are reported to be silenced via DNA
methylation in MPM. Here, we confirm these studies by ana-
lyzing SFRP mRNA expression levels and DNA methylation
status in seven cell lines. We first looked at mRNA expression
of SFRP1, SFRP2, SFRP4, and SFRP5 inMPMcell lines; SFRP3
was not included as it does not have a distinctive CpG island.
We compared the mRNA expression of SFRP genes in MPM
cell lines to the noncancer MeT-5A and found that for most
of our MPM cell lines SFRP genes are downregulated
(Figure 1(a)).We treated theseMPMcell lineswith ademethy-
lating agent (decitabine). Results indicated that expression of
at least two SFRP genes was reactivated in everyMPMcell line
(Figure 1(a) right), which is a strong indication ofDNAhyper-
methylation. We then analysed DNA methylation status in
MPM cells. We narrowed down our focus to SFRP2 and


























































































































































































































































































Figure 1: Asbestos-induced downregulation of tumour suppressor gene expression due to DNA methylation. (a) Basal expression and
demethylated expression of mRNA of SFRP genes were determined by RT-qPCR in 7 MPM cell lines and in MeT-5A. Results were
normalized to 18S and are expressed relative to the expression of MeT-5A or control untreated cells. (b) The methylation status of SFRP2
and SFRP5 were determined by MSP cell lines. (c) The expression of SFRP1 was determined by RT-qPCR and DNA methylation by
qMSP in MeT-5A cells with or without asbestos exposure. mRNA expression or methylation status was presented as fold change to
parental untreated MeT-5A cells. (M=methylated; U= unmethylated, BC= buffy coat isolated from a healthy donor, IVD=universal
methylated DNA control).
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Investigating the DNA methylation status of SFRP2 and
SFRP5 inMPMcells lines revealed thatSFRP2 and SFRP5were
consistently methylated and became unmethylated when
treated with decitabine (Figure 1(b)). Our results reconfirm
previous publications that SFRPs are downregulated through
hypermethylation inMPM cells [33, 34].
3.1.1. The Effect of Asbestos Exposure on Tumour Suppressor
Genes SFRP1 and SFRP2. We next studied the relationship
between chronic asbestos exposure and tumour suppressor
gene regulation. We speculated that the mechanism of
asbestos-induced carcinogenesis could involve the suppres-
sion of tumour suppressor genes by DNA hypermethylation,
as it is known that DNA methylation plays a major role in
carcinogenesis [21, 31, 35]. The mesothelial cell line MeT-
5A was continuously exposed to low-level chrysotile asbestos
(1 μg/cm2) for 3 months. Low levels of chrysotile were in line
with those not inducing apoptosis in previous studies but did
induce ROS (data not shown). RNA and DNA were isolated
from cells harvested at different time points. We selected
SFRP1 and SFRP2 for mRNA expression and DNA methyla-
tion studies. In the above results, we observed high expres-
sion of SFRP1 in the MeT-5A cell line. We also observed
that SFRP2 was highly upregulated after decitabine treat-
ment. Therefore, we analysed mRNA expression and the
DNA methylation status of the SFRP1 and SFRP2 genes
following chronic asbestos exposure. Prior to asbestos
exposure, SFRP1 and SFRP2 were highly expressed and
unmethylated in MeT-5A. After asbestos exposure, SFRP1
and SFRP2 mRNA expression was progressively downregu-
lated from day 7 to day 27 (Figure 1(c)). In these samples,
we also observed low levels of DNA methylation (data not
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Figure 2: SFRP2 or SFRP5methylation inMPM FFPE samples and overall survival. (a) MSP of SFRP2 and SFRP5 using FFPE samples, shown
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(c)
Figure 3: SFRP2 or SFRP5 re-expression in MPM cell lines inhibits cell growth and colony formation. (a) Protein re-expression of SFRP2 and
SFRP5 was confirmed with immunofluorescence SFRP2 or SFRP5 red or β-actin in green and DAPI nuclear staining in blue. (b) 11 MPM cell
lines and MeT-5A were transfected with pcDNA3.1 or pcDNA3.1-SFRP2 or pcDNA3.1-SFRP5, and plates were harvested every 24 hrs
for a total of 120 hrs. Cell proliferation was determined by SYBG assay, significant difference between SFRP2 and SFRP5 to control as ∗ with
p < 0 05. (c) The clonogenic potential was assessed by plating 2500 transfected cells per 96 wells and then transferring to a 6-well plate at
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Figure 4: Detection of SFRPs in noninvasive plasma samples using droplet digital PCR. (a) Primers for confirmation of methylation of SFRP
genes using cell lines as control with ddPCR EvaGreen assay. (b) Representative ddPCR results using noninvasive MPM plasma samples
methylated or unmethylated fragments were detected using the same primer sets from Figure 4(a). (c) SFRP methylation in MPM and
normal healthy control plasma was tested using the same ddPCR primer sets and conditions; result output was presented as total copy
number detected per 20 μL ddPCR reaction. ddPCR results showed significant (p < 0 05∗) separation of normal (green) and MPM plasma
samples (red) of SFPR2 and SFRP5.
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shown), and these methylation results were not significantly
different between asbestos treatment and controls. We then
measured the DNA methylation status of SFRP1 and SFRP2
in later samples by qMSP. Our qMSP results for SFRP1 and
SFRP2 showed increased methylation from day 81 and
becoming highly methylated by day 108 (Figure 1(c)).
This is the first time that exposure of MeT-5A nonmalig-
nant cells to asbestos has been shown to cause downregulated
mRNA expression and increased DNAmethylation of SFRP1
and SFRP2. Although asbestos is a known carcinogen and
exposure is highly linked to development of mesothelioma,
DNA methylation of SFRP genes has not previously been
explored. Previous research hypothesised a link between
chronic inflammation elicited by asbestos fibres in the meso-
thelial cavity, damaged scar tissue induced by the chronic
inflammation, and inhibition by asbestos-induced ROS of
repair of the scar tissue [36, 37]. Our results confirm our
hypothesis that asbestos exposure induces an increase in
DNA methylation of the promoter of the SFRP1 and SFRP2
tumour suppressor genes and downregulation of mRNA of
those genes.
3.2. SFRP2 and SFRP5 Are Hypermethylated in MPM
Tumour Samples. We next analysed the methylation status
of SFRP2 and SFRP5 in 66 MPM patient samples because
these two genes were the most frequently downregulated
and methylated in our MPM cell lines. Representative meth-
ylation results are shown in (Figure 2(a)). Out of a total of 66
MPM samples, we found that 56% (40 out of 66) and 70% (46
out of 66) have methylation of SFRP2 and SFRP5, respec-
tively, with both SFRP2 and SFRP5 methylation detected in
44% (29 out of 66) samples. Methylation of SFRP2 and SFRP5
was not detected in samples from healthy normal donors.
The effect of SFRP2 or SFRP5 DNA methylation on overall
survival of MPM patients was assessed using the Kaplan-
Meier method (Figure 2(b)). The Cox regression analysis
indicated an association between overall survival and SFRP2
(p = 0 06) and SFRP5 (p = 0 56) DNA methylation status in
our sample series. The lack of a significant correlation
between overall survival of SFRP2 and SFRP5 DNA methyla-
tion inMPM contrasts with the situation in colorectal cancer,
where SFRP1 and SFRP2 methylation has potential as an
early diagnostic epigenetic biomarker [38].
3.3. The Functional Effects of SFRP2 and SFRP5 in MPM Cell
Invasion and Colony Formation. Previous research has
reported that the SFRP antagonists of the Wnt pathway are
potential tumor suppressor genes and are frequently silenced
andmethylated in many cancers [21, 33, 34, 39]. In our study,
we show that long-term exposure of asbestos in an in vitro
model leads to downregulation of SFRP tumour suppressor
geneexpressionand thisdownregulation isviaDNAhyperme-
thylation of their promoter regions. Our results for promoter
methylation of SFRP2 and SFRP5 inMPM suggested that they
are downregulated in MPM by hypermethylation and thus
mayhave tumour suppressorpotential inMPM.To investigate
this, we cloned the ORF of both genes and transfected
constructs containing these genes into MPM cells. Confirma-
tion of overexpression of SFRP2 and SFRP5 is shown in
Figure 3(a). In all 11 MPM cell lines tested, both SFRP2 and
SFRP5 separately suppressed MPM cell growth compared to
control transfections (Figure3(b),p < 0 05).The immortalised
MeT-5A cell line showed much less suppression when trans-
fected and this was not significant (Figure 3(c), p = 0 07).
Ectopic expression of SFRP2 or SFRP5 also inhibited the
ability of MPM cells to form colonies (Figure 3(c)). Our
results confirm that SFRP2 and SFRP5 are tumour suppres-
sors of mesothelioma, similar to reports by others [33, 34].
3.4. Methylated SFRP2 and SFRP5 Promoter DNA Is
Detectable in MPM Patient Plasma. As SFRP2 and SFRP5
are frequently methylated in MPM tumour samples, we
speculated that the methylated DNA might be released by
tumour cells and detectable in plasma. We employed recently
available droplet digital PCR technology because it allows
quantitative and sensitive detection of nucleic acids. We
first optimized ddPCR condition with cell line samples
(Figure 4(a)) and then applied this optimized method to
the analysis of patient plasma samples (Figure 4(b)). Using
the positive population shown in Figure 4(b), we then mea-
sured methylation status of SFRPs in samples from 10
MPM patients and 10 age-matched controls. We were able
to detect methylated DNA from SFRP2 and SFRP5 with both
showing a distinctive cut-off between patient and healthy
normal plasma (Figure 4(c)). We were also able to detect
SFRP1 and SFRP4 methylation in plasma samples; however,
there was no distinctive separation of patients and controls.
There are many studies reporting detection of biomarkers
in noninvasive samples from cancer patients, including
sputum (lung cancer) [40], urine (bladder cancer) [41, 42],
plasma (breast cancer) [43], and stool (colon cancer)
[44, 45]. Although we have demonstrated that methylated
SFRPs can be detected in plasma of MPM patients, the small
sample size means that we are not able to make a definitive
conclusion about whether we can use this finding as a diag-
nostic marker for MPM. These promising early data require
validation in a larger series of samples from MPM patients
and controls.
4. Conclusion
Our gene regulation, DNA methylation, cell growth, and col-
ony formation results indicate that SFRP2 and SFRP5 both
act as tumour suppressors of MPM and are silenced by
DNA hypermethylation. SFRP1 and SFRP2 gene expression
was downregulated by prolonged asbestos exposure in
immortalised noncancer mesothelial cells. We also show that
methylation of SFRP2 (56%) and SFRP5 (70%) is common in
patient samples. The noninvasive detection of SFRP2 and
SFRP5 in blood plasma samples demonstrates the potential
of using DNA methylation status as a noninvasive epigenetic
biomarker for MPM.
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